BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.
Featured Science Oral Presentation:
Acoramidis Reduces All-Cause Mortality (ACM) and
Cardiovascular-Related Hospitalization (CVH): Initial Outcomes
from the ATTRibute-CM Open-Label Extension (OLE) Study
Session Title: Featured Science: Amyloid,
Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and
Specific Populations
Presenter: Daniel Judge, M.D. of Medical
University of South Carolina
Date: Monday, November 18 at 9:45 am CT/10:45
am ET
Moderated Digital Posters:
Costs and Healthcare Resource Utilization in Transthyretin
Amyloid Cardiomyopathy Exceeds That of Generalized Heart
Failure
Session Title: Socioeconomic Insights and
Innovations in Heart Failure
Presenter: Justin Grodin, M.D. of UT
Southwestern Medical Center
Date: Sunday, November 17 at 10:00 am CT/11:00
am ET
Evolving Baseline Risk in Patients with Transthyretin Amyloid
Cardiomyopathy: A Systematic Literature Review of Clinical
Trials
Session Title: Cardiac Amyloidosis 2024:
Advances in Prognostication and Management
Presenter: Ahmad Masri, M.D. of Oregon Health
& Science University
Date: Sunday, November 17 at 11:10 am CT/12:10
pm ET
Acoramidis Improved Survival in Patients with Transthyretin
Cardiac Amyloidosis Regardless of Prior Cardiovascular
Hospitalization
Session Title: Cardiac Amyloidosis 2024:
Advances in Prognostication and Management
Presenter: Kevin Alexander, M.D. of Stanford
University School of Medicine
Date: Sunday, November 17 at 11:20 am CT/12:20
pm ET
The presentation and posters will be available following the sessions on the Presentations page within the Investors section of the BridgeBio website at https://investor.bridgebiodev.wpengine.com.
About BridgeBio Pharma, Inc.
BridgeBio Pharma (BridgeBio) is a commercial-stage
biopharmaceutical company founded to discover, create, test and
deliver transformative medicines to treat patients who suffer
from genetic diseases. BridgeBio’s pipeline of development
programs ranges from early science to advanced clinical trials.
BridgeBio was founded in 2015, and its team of experienced drug
discoverers, developers and innovators are committed to applying
advances in genetic medicine to help patients as quickly as
possible. For more information visit bridgebiodev.wpengine.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Contact:
Vikram Bali
[email protected]
(650)-789-8220